Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Phillippa Carling


Postdoctoral Research Scientist

Developing new therapies for neurodegenerative conditions has proved uniquely challenging, and it has become clear that academic research has a valuable role to play in identifying promising new treatments for neurodegenerative conditions. We have an exciting collaboration with the Oxford Drug Discovery Institute to bring expertise from the pharmaceutical industry into an academic setting.

Autophagy and lysosome dysfunction are common hallmarks of many neurodegenerative conditions characterised by an accumulation of toxic protein aggregates, such as α-synuclein in Parkinson’s disease (PD) and Tau or amyloid β-protein (Aβ) in Alzheimer’s disease (AD). I am using the latest technology to develop high throughput compound screening assays in order identify new compounds regulating protein homeostasis and lysosome function, in the hope of development novel treatments.